Authors : Pathuni Hema Geethika; Chintapalli Veera Venkata Sireesha; Jasthi Satya Gayatri Devi

Volume/Issue : Volume 10 - 2025, Issue 7 - July

---

Google Scholar : https://tinyurl.com/23sysydc

Scribd : https://tinyurl.com/3hdtzwf3

DOI : https://doi.org/10.38124/ijisrt/25jul1719

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

---

Abstract : Alzheimer's disease is a chronic, progressive neurodegenerative disorder marked by cognitive decline, behavioral changes, and eventual loss of independent function. It is the leading cause of dementia globally, posing a significant social, economic, and medical burden. Recent scientific breakthroughs have shifted the focus from symptomatic treatment to early diagnosis and disease-modifying interventions. This review explores the molecular pathogenesis of AD, advances in early diagnostic techniques including novel biomarkers and neuroimaging, and emerging therapeutics ranging from monoclonal antibodies to gene therapy and lifestyle interventions. By integrating early detection strategies with emerging therapeutics, we move closer to intercepting AD at its earliest and most manageable stage.

Keywords : Alzheimer’s, Neurological Loss, MRI, Antibodies, Personalized Medicines.

References :

1. Jack CR Jr., Bennett DA, Bleeow K, et al. (2018). NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disese. Alzheimer’s & Dementia, 14(4), 535-562.
2. Cummings J, Lee G, Ritter A, Zhong K. (2024). Alzheimer’s disease drug development pipeline: 2024. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 10:e12488.
3. Long JM, Holtzman DM. (2019). Alzheimer disease: An update on pathobiology and Treatment Strategies.
4. Van Dyck CH, Swanson CJ, Aisen P,et al.(2023). Lecanemab in early Alzheimer’s disese. New England Journal of Medicine, 388(1), 9-21.
5. Hampel H, O’Bryant SE,Molinuevo JL, et al. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639-652.
6. Henstridge CM, Hyman BT, Spires-Jones TL. (2019). Beyond the neuron-cellular inteeractions early in alzheimer disesse pathogenesis. Nature Reviews Neuroscience, 20(2), 94-108.
7. Dementia Prevention,Intervention, and care :2020 report of the Lancet Commission. The Lancet, 396(10248),413-446.
8. Alzheimer’s Association. (2024). 2024 Alzheeimer’s Disease Facts and Figures. Alzheeimer’s & Dementia, 20(3), 321-418.
9. Hampel H, Hardy J, Blennow K, et al. (2021). The amyloid-βpathway in Alzheimer’s disease. Molecular psychiatry, 23,, 5481-5503.
10. Ferreira D, Nordberg A, Westman E. (2020). Biomarkers for Alzheimer’s disease: current status and prospects for the future. Journal of Internal Medicine, 287(3), 232-252.